New York, New York, United States The fund was located in North America if to be more exact in United States. The leading representative office of defined Corporate Investor is situated in the New York.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Blue Ox Healthcare Partners, startups are often financed by Domain Associates, RMI Partners, Catalyst Health Ventures. The meaningful sponsors for the fund in investment in the same round are Viventures, Varian, Sabby Management.
Among the most popular fund investment industries, there are Health Diagnostics, Biotechnology. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Epic Sciences.
The high activity for fund was in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year.
| Fund Name | Location |
| Accelr8 | Boston, Massachusetts, United States |
| Anthem Capital Management | Baltimore, Maryland, United States |
| CM Venture Capital | China, Shanghai |
| Genesis Financial | - |
| Haitun Baobao | China, Guangdong, Shenzhen |
| Laetitia Garriott de Cayeux | New York, New York, United States |
| Neoteric Infomatique | India, Maharashtra, Mumbai |
| Renren Inc. | Chaoyang, China, Liaoning |
| SGR Investments | - |
| Tamar Capital | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Gemelli Biotech | $19M | 22 Jun 2022 | Raleigh, North Carolina, United States |
– Sera Prognostics, Inc. from Salt Lake City develops a blood-based biomarker test to predict the risk of preterm birth.
– Series E $100m round brings company valuation to more than $1b.
– The round was led by Vivo Capital, aMoon Fund, Parian Global and others, with participation from existing investors Anthem, Inc., and Blue Ox Healthcare Partners.
– The new investment will be aimed at commercializing its PreTRM® testing, accelerating the development of its pipeline of biomarker tests to predict other major conditions of pregnancy, and developing testing capacity for over 3 million annual pregnancies that are candidates for its PreTRM® Test in the United States.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Gemelli Biotech | $19M | 22 Jun 2022 | Raleigh, North Carolina, United States |
